A Phase II Study of Pegylated Interferon Alfa-2b for the Adjuvant Treatment of Melanoma Subjects in Russia (MK-4031-400)

A Phase II Study of Pegylated Interferon Alfa-2b in AJCC Stage III (TxN1-2M0) Melanoma Subjects After Regional Lymph Node Dissection in Russia

This study will assess the safety of Pegylated Interferon Alfa-2b (PEG-IFN) as an adjuvant treatment for melanoma.

Study Overview

• Status: Completed
• Conditions: Melanoma
• Intervention / Treatment: Biological: Pegylated Interferon Alfa-2b; Biological: Pegylated Interferon Alfa-2b

• Study Type: Interventional
• Enrollment (Actual): 33
• Phase: Phase 2

Participation Criteria

Eligibility Criteria

• Ages Eligible for Study: 18 years and older (Adult, Older Adult)
• Accepts Healthy Volunteers: No
• Genders Eligible for Study: All

Description

Inclusion Criteria:

• Competent to self-administer the subcutaneous injections of PEG-IFN
• Histologically documented involved regional lymph nodes of a primary cutaneous melanoma or unknown primary, meeting the study's staging criteria
• Had the primary melanoma completely resected with adequate surgical margins and undergone operation for positive regional lymph nodes within 84 days of study start
• Eastern Cooperative Oncology Group Performance Status (ECOG PS) score of 0 or 1
• Adequate hepatic, renal and bone marrow function as defined by study parameters obtained within 4 weeks prior to study start
• For a female subject who is of childbearing potential or male participant with female sexual partner who is of childbearing potential, agree to use acceptable methods of contraception for at least 2 weeks prior to study start and continue until at least 6 months after last dose of study medication, or longer if dictated by local regulations

Exclusion Criteria:

• Mucous membrane melanoma or ocular melanoma
• Known hypersensitivity to the components of study drug (including acetaminophen), or its analogs
• Evidence of distant or non-regional lymph node metastases or in-transit metastases
• Disease that cannot be completely surgically resected
• Prior malignancy within the past 5 years other than surgically cured non-melanoma skin cancer or cervical carcinoma in situ
• Severe cardiovascular disease, i.e. arrhythmias, requiring chronic treatment, congestive heart failure or symptomatic ischemic heart disease
• Hepatic decompensation
• Thyroid dysfunction not responsive to therapy
• Uncontrolled diabetes mellitus
• Clinically active autoimmune disease
• Clinically active and/or uncontrolled infection, including active hepatitis
• Human immunodeficiency virus (HIV)
• History of neuropsychiatric disorder requiring hospitalization
• Actively abusing alcohol or drugs
• Pregnant, lactating, or of reproductive potential and not using an effective means of contraception
• Medical condition requiring chronic systemic corticosteroids
• Received any experimental therapy within 30 days prior to enrolling in this study
• Received any prior chemotherapy, immunotherapy, hormonal or radiation therapy for melanoma
• Previously received interferon-α for any reason
• Known serious hypersensitivity reaction to PEG-IFN or interferon alfa-2b

Study Plan

How is the study designed?

Design Details

• Primary Purpose: Treatment
• Allocation: N/A
• Interventional Model: Single Group Assignment
• Masking: None (Open Label)

Number of Arms

1

Arms and Interventions

Participant Group / Arm	Intervention / Treatment
Experimental: PEG-IFN; 6.0 μg/kg/week subcutaneous administration during the Induction Phase of 8 weeks followed by a dose of 3.0 μg/kg/week subcutaneous administration in the Maintenance Period (Week 8 to Month 12)	Biological: Pegylated Interferon Alfa-2b; 6 μg/kg, weekly dosing, subcutaneous administration, Induction Phase - first 8 weeks; Biological: Pegylated Interferon Alfa-2b; 3 μg/kg SC once weekly for a 42-week maintenance phase (for a total treatment of up to approximately 1 year)

What is the study measuring?

Primary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Percentage of Participants Experiencing Adverse Events (AEs)	An adverse event was any unfavorable and unintended change in the structure, function, or chemistry of the body whether or not considered related to the study treatment.	From first dose through follow-up; up to 13 months
Percentage of Participants Discontinuing Study Drug Because of AEs	An adverse event was any unfavorable and unintended change in the structure, function, or chemistry of the body whether or not considered related to the study treatment.	From first dose to last dose of treatment; up to 12 months

Collaborators and Investigators

• Sponsor: Merck Sharp & Dohme LLC

Study record dates

Study Major Dates

• Study Start (Actual): August 19, 2014
• Primary Completion (Actual): March 21, 2016
• Study Completion (Actual): March 21, 2016

Study Registration Dates

• First Submitted: June 2, 2014
• First Submitted That Met QC Criteria: June 2, 2014
• First Posted (Estimate): June 4, 2014

Study Record Updates

• Last Update Posted (Actual): August 23, 2018
• Last Update Submitted That Met QC Criteria: July 24, 2018
• Last Verified: July 1, 2018

More Information

Terms related to this study

• Additional Relevant MeSH Terms: Neoplasms by Histologic Type; Neoplasms; Neuroectodermal Tumors; Neoplasms, Germ Cell and Embryonal; Neoplasms, Nerve Tissue; Neuroendocrine Tumors; Nevi and Melanomas; Melanoma; Physiological Effects of Drugs; Anti-Infective Agents; Antiviral Agents; Antineoplastic Agents; Immunologic Factors; Interferons; Interferon-alpha; Interferon alpha-2; Peginterferon alfa-2b
• Other Study ID Numbers: 4031-400

Plan for Individual participant data (IPD)

• Plan to Share Individual Participant Data (IPD)?: YES
• IPD Plan Description: https://www.merck.com/clinical-trials/pdf/ProcedureAccessClinicalTrialData.pdf